Loading...
Although rhinoviruses cause over two-thirds of upper respiratory tract infections, no vaccines or antiviral therapies are available for these microbes. Vaccine development is a daunting task, because over 100 rhinovirus types exist, and immunity is type-specific. A novel therapeutic approach exploits the fact that most rhinovirus types attach to cells by a single cellular receptor, intercellular adhesion molecule 1 (ICAM-1). In this placebo-controlled, manufacturer-sponsored study, tremacamra, a soluble ICAM-1 designed to block the viral receptor, was administered to volunteers inoculated with rhinovirus type 39. Ninety-six of 177 evaluable subjects received placebo, and 81 received tremacamra, each given intranasally six times a day for 7 …